Pintail

Pintail Therapeutics is an early-stage biotechnology company focused on the discovery and development of novel molecular glues and targeted protein degradation (TPD) therapies. Founded by industry veterans with deep expertise in the TPD space, the company leverages a proprietary platform to identify small molecules that induce proximity between disease-causing proteins and E3 ubiquitin ligases. By facilitating the degradation of previously "undruggable" targets, Pintail aims to address significant unmet needs in oncology and immunology. The company operates primarily in a stealth or early-development mode, focusing on building a robust pipeline of proximity-inducing agents.